HESTERBIO — Hester Biosciences Income Statement
0.000.00%
- IN₹14.58bn
- IN₹16.56bn
- IN₹3.11bn
- 82
- 13
- 57
- 50
Annual income statement for Hester Biosciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,143 | 2,350 | 2,661 | 3,045 | 3,111 |
| Cost of Revenue | |||||
| Gross Profit | 1,540 | 1,586 | 1,705 | 1,823 | 1,981 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,590 | 1,916 | 2,362 | 2,663 | 2,659 |
| Operating Profit | 554 | 434 | 299 | 383 | 452 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 501 | 535 | 402 | 320 | 396 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 347 | 395 | 280 | 212 | 288 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 344 | 393 | 266 | 189 | 275 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 344 | 393 | 266 | 189 | 275 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 43.2 | 46.1 | 31.3 | 21.3 | 32.7 |
| Dividends per Share |